CA
NZ
UK
AU
IND
US
Evaxion A/S (NASDAQ: EVAX) released fresh preclinical results for its cytomegalovirus (CMV) vaccine candidate EVX‑V1 at the International Herpesvirus Workshop in Montreal. The data highlight a novel, AI‑driven approach that could broaden the company's pipeline and influence investor sentiment as the share price dipped …
OmniAb Inc. Has named Amechi Nwachuku as its new Chief Operating Officer, marking a significant shift in its executive team. The appointment, effective July 13, 2026, follows a career spanning life sciences, diagnostics, and pharmaceuticals. Nwachuku’s role will focus on operational strategy as OmniAb …
A recent collaboration between Arovella Therapeutics and a contract research organization reflects increasing activity in the cell therapy field, particularly within oncology. The partnership demonstrates the rising need for specialized testing services in drug development, which may benefit firms involved in precision medicine.
Cerus Corp (NASDAQ: CERS), a company specializing in blood safety technologies, has announced a leadership transition by appointing its former chief executive to the role of Executive Chairman. The change became effective in the summer of 2026, marking a shift in the company’s executive …
DarioHealth Corp. (NASDAQ: DRIO) disclosed a shift in its executive leadership structure following an extended medical leave taken by its President and Chief Commercial Officer. The announcement outlines how the firm will navigate the interim period without the executive.
The U.S. Food and Drug Administration’s proposed rule change could reshape drug manufacturing dynamics, benefiting contract development and manufacturing organizations (CDMOs) while tightening oversight of overseas production. The move aligns with broader efforts to reduce dependence on imported medicines and strengthen domestic supply chains, …
Amphastar Pharmaceuticals (NASDAQ: AMPH) has strengthened its governance structure by adding a new independent director. The move reflects the company’s ongoing efforts to enhance board oversight as it navigates the competitive pharmaceutical sector.
Key HighlightsRobert W. Baird lowered its price target for Circle Internet Group to $100 per share, down from $138.The adjustment reflects a reassessment of Circle Internet’s revenue trajectory, though BDMD’s direct exposure remains unclear.Investors reacted swiftly, with BDMD trading near its adjusted level in …
Concentra Group Holdings Parent, Inc. (NYSE: CON) reported a senior leadership transition that will affect its medical affairs function. Dr. John R.
Elite Health Systems Inc. Has launched a formal review of strategic alternatives as it grapples with intensifying competition and regulatory demands in the Medicare Advantage space. The move signals potential shifts in the company’s structure or ownership as it seeks to bolster its market …
Please wait processing your request...